Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-874-0 | CAS number: 100-64-1
Health surveillance data
Administrative data
- Endpoint:
- health surveillance data
- Type of information:
- other: workplace experience
- Adequacy of study:
- supporting study
- Study period:
- not stated
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Imprecise description of exposure, impurities or exposure to other chemicals as causative or confounding agents cannot be excluded
Data source
Reference
- Reference Type:
- review article or handbook
- Title:
- Tier 1 Screening SIDS Dossier on the HPV Phase ... Chemical Cyclohexanone Oxime CAS No. 100-64-1
- Author:
- Anonymous
- Year:
- 2 008
- Bibliographic source:
- online: http://www.epa.gov/hpv/pubs/summaries/cycloxim/c16215rr.pdf (as of Jan 2013)
- Report date:
- 2008
Materials and methods
- Study type:
- health record from industry
- Endpoint addressed:
- other: haematotoxicity, dermal effects
- Principles of method if other than guideline:
- workplace experience
- GLP compliance:
- no
Test material
- Reference substance name:
- Cyclohexanone oxime
- EC Number:
- 202-874-0
- EC Name:
- Cyclohexanone oxime
- Cas Number:
- 100-64-1
- Molecular formula:
- C6H11NO
- IUPAC Name:
- cyclohexanone oxime
- Test material form:
- not specified
- Details on test material:
- no data
Constituent 1
Method
- Details on study design:
- no data
Results and discussion
- Results:
- This secondary quotation of Finkel, A.J. (in Hamilton and Hardy’s Industrial Toxicology, 4th Edition, John Wright PSG, Boston, MA, 1983) reports haematological disorders in humans exposed to the test substance.
It was also stated that dermatitis and skin sensitization may also be potential effects of occupational exposure.
No further details were provided.
Applicant's summary and conclusion
- Conclusions:
- No definite conclusions can be drawn from this information, but haematological disorders are in accordance with the haematological effects observed in animal studies (compare e.g. chapter 7.5.1)
- Executive summary:
The secondary source information reports haematological disorders in humans exposed to the test substance. It was also stated that dermatitis and skin sensitization may also be potential effects of occupational exposure. No further details were provided.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
